The relapse-free survival (RFS) and overall survival (OS) of breast cancer patients as analyzed by the Kaplan–Meier method, and a log-rank test showed that patients with low expression level of TMCC3 in tumor had significantly greater RFS (p < 0.001) and OS (p < 0.001) than patients with high expression levels (Fig. 6a, b). Here, TMCC3 is linked to breast cancer.